Key result
Anticoagulation in critically ill patients with trigger-induced atrial fibrillation was not associated with a decreased incidence of thromboembolism (OR 0.87; 95% CI 0.61-1.30).
Why the study?
Current guidelines provide no definitive recommendations on anticoagulation for critically ill patients with trigger-induced atrial fibrillation.
Does anticoagulation reduce thromboembolism or mortality in critically ill patients with trigger-induced atrial fibrillation?
Meta-Analysis
Does anticoagulation reduce thromboembolism or mortality in critically ill patients with trigger-induced atrial fibrillation?
In critically ill patients with trigger-induced atrial fibrillation, anticoagulation prescription is highly variable and does not significantly reduce short-term thromboembolic risk, highlighting the need for individualized decision-making.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in trigger-induced AF; leaves open whether RCTs confirm mortality benefit.
Introduction Current guidelines provide no definitive recommendations on anticoagulation for critically ill patients with trigger-induced atrial fibrillation. This study aimed to assess the association of anticoagulation prescription with thromboembolism, bleeding, and mortality outcomes and evaluate anticoagulation prescription patterns and the initiation rate in high-risk patients based on CHA₂DS₂-VASc scores. Methods A systematic literature search identified studies on critically ill patients with trigger-induced AF, reporting on thromboembolism, bleeding, mortality and anticoagulation prescription. Anticoagulation prescription rates and CHA₂DS₂-VASc scores were correlated. A meta-analysis was conducted to evaluate the incidence of thromboembolism, bleeding, and mortality in relation to anticoagulation use, stratified into short-term and long-term outcomes. Results The analysis included 26 studies, with anticoagulation rates ranging from 3% to 86%. Among studies reporting CHA₂DS₂-VASc scores, over 50% of patients had scores ≥2. In the meta-analysis (six studies, all observational studies mainly reporting on infection/sepsis as precipitating factor) prescription of anticoagulation demonstrated no association with a decreased incidence of thromboembolism (OR 0.87, 95% CI 0.61 to 1.30) or an increased incidence of bleeding (OR 0.97, 95% CI 0.83 to 1.13). The use of anticoagulation was associated with reduced short-term mortality (OR 0.64, 95% CI 0.41 to 0.99). The prescription of anticoagulation was associated with an increased long-term risk of thromboembolism (OR 1.45, 95% CI 1.04 to 2.03) but not bleeding (OR 1.20, 95% CI 0.97 to 1.48). Conclusions In critically ill patients with trigger-induced atrial fibrillation anticoagulation prescription patterns are highly variable and do not align with the CHA₂DS₂-VASc recommendation. The use of anticoagulation in these patients was not associated with a reduced stroke risk or an increased risk of bleeding. Therefore, both the potential benefits and risks of anticoagulation in this population remain largely unknown, and its use should be carefully considered on an individual basis.
No takes yet. Share an insight, caveat, or question.
Koolwijk et al. (2025) conducted a meta-analysis in Trigger-induced atrial fibrillation in critically ill patients. Anticoagulation vs. No anticoagulation was evaluated on Incidence of thromboembolism (OR 0.87, 95% CI 0.61 to 1.30). Anticoagulation in critically ill patients with trigger-induced atrial fibrillation was not associated with a decreased incidence of thromboembolism (OR 0.87; 95% CI 0.61-1.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: